Treatment of Hot Flashes and Osteoporosis (Loss of Bone)

A potential treatment is under development at Endoceutics for vasomotor symptoms of menopause without the risk of breast cancer associated with estrogens, and prevention of osteoporosis.

This combination therapy may also help prevent breast and uterine cancer, in addition to having other observed favorable effects including decrease in cholesterol and fat accumulation.

Mechanism of Action

The combination of prasterone (DHEA), the cell-specific supplier of intracellular estrogens and androgens, with a highly specific blocker of estrogen action in the breast and uterus (acolbifene) has positive effects in bone where it decreases bone loss (action of acolbifene) and, simultaneously, (action of DHEA) stimulates bone formation.

Acolbifene, Endoceutics estrogen receptor modulator (SERM) has been tested in several clinical studies performed in healthy postmenopausal women and in women with advanced breast cancer where positive results have been obtained. The potent inhibitory effect of acolbifene on cell proliferation in the mammary gland of women at high risk of breast cancer was observed in a study performed by the US National Cancer Institute.  In the Phase II study performed by the US National Cancer Institute, a 77% decrease of the proliferation index was demonstrated in the mammary gland.

The pure antagonistic activity of acolbifene demonstrated in human breast and uterine cancer cells strongly supports its potential long-term use in women with a high probability of breast and uterine cancer prevention.

In addition, in preclinical studies, acolbifene has been observed to decrease bone loss and had beneficial effects on lipids and fat accumulation.

Endoceutics approach

A results-oriented approach and the implementation of effective solutions.

Treatment of Breast Cancer

What is a Hormone-Dependent Cancer?


Exploring Endometriosis

Endometriosis is a frequent gynecological disease responsible for a significant proportion of infertility



The resulting hormonal deficiency is responsible for a series of symptoms typical of post-menopause which vary from woman to woman


Dyspareunia (GSM/VVA)

Genitourinary Syndrome of Menopause (GSM) and Vulvovaginal Atrophy (VVA)


Men's health

Prostate Cancer and Anti-androgens